On January 1, 2026, Novo Nordisk Inc. (labeler code 00169), and Novo Nordisk Pharma, Inc. (labeler code 73070), herein referred to collectively as “Novo Nordisk,” will begin extending the 340B ceiling price for all Fiasp® and NovoLog® branded and unbranded biologic1 products included on CMS’s Initial Price Applicability Year 2026 Medicare Drug Price Negotiation Program Selected Drug list (Rebate Model Products) through a rebate pursuant to the Health Resources and Services Administration’s 340B Rebate Model Pilot Program (Rebate Model).
As a result, the 340B ESP™ Second Sight Solutions platform (ESP™ Platform) will no longer accept claim level detail for the Rebate Model Products beginning January 1, 2026.
Please see Novo Nordisk’s October 31, 2025 notice to Covered Entities (CEs) on the Novo Nordisk website, at https://www.novonordisk-us.com/partnering-and-innovation/340b-program-updates.html, and Second Sight Solutions’ Beacon 340B technology platform website, at
https://cm.beaconchannelmanagement.com/, for further details regarding submission of Rebate Model Product claim data to access 340B rebates.
This notice supersedes previous Novo Nordisk policies2 to the extent such polices require CEs to submit Rebate Model Product claims data via the ESP™ Platform.
All other requirements set forth in Novo Nordisk’s May 1, 2024, Notice Regarding Revised Limitation on Hospital and Grantee 340B Contract Pharmacy Distribution, including contract pharmacy designation requirements applicable to all Novo Nordisk products, inclusive of Rebate Model Products, continue in effect without modification.
1 The unbranded biologic insulin aspart products manufactured by Novo Nordisk Pharma, Inc. will be discontinued on December 31, 2025.
2 Novo Nordisk’s previous policies were communicated on December 1, 2020, February 1, 2022, December 2, 2022, June 1, 2023, and May 1, 2024.